pRL-TK 4x wt Citations (12)

Originally described in: Specificity of microRNA target selection in translational repression.
Doench JG, Sharp PA Genes Dev. 2004 Mar 1. 18(5):504-11. PubMed Journal

---

Articles Citing pRL-TK 4x wt

Articles
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. Mudianto T, Campbell KM, Webb J, Zolkind P, Skidmore ZL, Riley R, Barnell EK, Ozgenc I, Giri T, Dunn GP, Adkins DR, Griffith M, Egloff AM, Griffith OL, Uppaluri R. Clin Cancer Res. 2021 Apr 15;27(8):2326-2339. doi: 10.1158/1078-0432.CCR-19-4179. Epub 2021 Feb 5. PubMed
SIPA1 Enhances Aerobic Glycolysis Through HIF-2alpha Pathway to Promote Breast Cancer Metastasis. Yao C, Weng J, Feng L, Zhang W, Xu Y, Zhang P, Tanaka Y, Su L. Front Cell Dev Biol. 2022 Jan 12;9:779169. doi: 10.3389/fcell.2021.779169. eCollection 2021. PubMed
Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-kappaB activity via UHRF1/DNMT1 complex. Lin S, Ruan H, Qin L, Zhao C, Gu M, Wang Z, Liu B, Wang H, Wang J. Int J Biol Sci. 2023 Jan 9;19(3):832-851. doi: 10.7150/ijbs.75963. eCollection 2023. PubMed
DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Miller AL, Perurena N, Gardner A, Hinoue T, Loi P, Laird PW, Cichowski K. Cancer Res. 2023 Jun 2;83(11):1800-1814. doi: 10.1158/0008-5472.CAN-22-0370. PubMed
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-kappaB/MGMT Axis. Liao X, Li Z, Zheng H, Qian W, Zhang S, Chen S, Li X, Tang M, Xu Y, Yu R, Li M, Song L, Li J. Mol Cancer Res. 2023 Jul 5;21(7):648-663. doi: 10.1158/1541-7786.MCR-22-1012. PubMed
UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer. Lin S, Xu H, Qin L, Pang M, Wang Z, Gu M, Zhang L, Zhao C, Hao X, Zhang Z, Ding W, Ren J, Huang J. Acta Pharm Sin B. 2023 May;13(5):2086-2106. doi: 10.1016/j.apsb.2023.02.015. Epub 2023 Feb 24. PubMed
CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression. Jin Z, Zhao L, Chang Y, Jin R, Hu F, Wu S, Xue Z, Ma Y, Chen C, Zheng M, Chang Y, Jin H, Xie Q, Huang C, Huang H. Cell Death Dis. 2023 Aug 26;14(8):563. doi: 10.1038/s41419-023-06088-1. PubMed
TNFRSF19 within the 13q12.12 Risk Locus Functions as a Lung Cancer Suppressor by Binding Wnt3a to Inhibit Wnt/beta-Catenin Signaling. Zuo X, Wang X, Ma T, Chen S, Cao P, Cheng H, Yang N, Han X, Gao W, Liu X, Sun Y. Mol Cancer Res. 2024 Mar 1;22(3):227-239. doi: 10.1158/1541-7786.MCR-23-0109. PubMed
Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3beta/TCF7/MMP9 pathway and synergies with capecitabine. Dai X, Chen W, Qiao Y, Chen X, Chen Y, Zhang K, Zhang Q, Duan X, Li X, Zhao J, Tian F, Liu K, Dong Z, Lu J. Cancer Lett. 2024 Feb 1;582:216596. doi: 10.1016/j.canlet.2023.216596. Epub 2023 Dec 13. PubMed
PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility. Jing N, Du X, Liang Y, Tao Z, Bao S, Xiao H, Dong B, Gao WQ, Fang YX. J Exp Clin Cancer Res. 2024 May 15;43(1):144. doi: 10.1186/s13046-024-03064-1. PubMed
RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis. Chen D, Ji F, Zhou Q, Cheung H, Pan Y, Lau HC, Liang C, Yang Z, Huang P, Wei Q, Cheung AH, Kang W, Chen H, Yu J, Wong CC. Cancer Res. 2024 Sep 4;84(17):2856-2872. doi: 10.1158/0008-5472.CAN-23-2081. PubMed
HIF-1alpha induced FGF18 alleviates renal ischemia/reperfusion injury via YAP. Wang N, Huang Z, Guan F, Wang J, Chen Y, Wang H, Jin L, Wang Y. FASEB J. 2024 Oct 15;38(19):e70092. doi: 10.1096/fj.202401238R. PubMed

If you have published an article using this material, please email us at to have your article added to this page.